NCT02138500View on ClinicalTrials.gov

A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

PF-06372865

Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.

DRUG

PF-06372865

Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.

DRUG

PF-06372865

Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.

Trial Locations (3)

06511

New Haven Clinical Research Unit, New Haven

06519

Anlyan Center, New Haven

06520

Yale University School of Medicine, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02138500 - A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865 | Biotech Hunter | Biotech Hunter